Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY03003 in early-stage Parkinson's disease
NCT04044547Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Nov 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing LY03003 with Placebo (2 arms). Primary endpoint: LY03003 concentration in plasma. Started Nov 2013; status: completed.
02
Drugs
Rotigotine extended-release microspheres
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04044547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044547.